Company intelligence / Profile preview

Vytala

Downingtown, Pennsylvania, United Statesvytalahealth.com ↗

Ownership: Private
Development stage: Commercial

Overview

Vytala’s lead product Seracal™ is a plant-based medical food clinically proven to improve fat and nutrient absorption in patients with malabsorption syndromes. Clinical studies have shown improved BMI, weight gain, height velocity, and absorption of essential nutrients in pediatric cystic fibrosis patients. The product is reimbursed by CMS and covered by most US insurers; early commercial uptake has been strong with high reorder rates.

Therapeutic areas: Metabolic DisordersRare DiseasesGastroenterology
Modalities: Medical food (plant-based)Crystalized lipid technology (Lym-X-Sorb®)
Industry: Food & Nutrition

Drug pipeline

1 asset

Lym-X-Sorb

Commercial

Indications: Fat malabsorption, Cystic fibrosis, Pancreatic insufficiency

Partnerships

HealthWell Foundation disease funds for patient access support

Beyond the preview

Go deeper on Vytala.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vytala.

Explore the full profile